About 5% of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, ...
Real-world data analysis of clinical characteristics and survival outcomes in Russian patients with NSCLC harboring EGFR mutations. A real-world study on first-line (1L) treatment for 46 advanced lung ...
Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas Authors retain all rights in any data supplements ...
This special issue of CURE Lung Cancer takes a deeper dive into ALK-positive non-small cell lung cancer. In this special issue of CURE, we examine some of the latest developments in the treatment of ...
In non-small-cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) rearrangement treated with crizotinib, progression-free survival (PFS) varies according to the ALK fusion variant.
Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer. The approval by the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results